Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In regards to the £120 price targets that some analysts had set over last 12months, we will not hitting that anytime soon.
The S&P fell through that special support level 4200 last night.
Could well be a similar move to that in October 2008-Feb 2009
Mr swing, meet roundabout.
Mr roundabout, meet swing.
etc,
etc.
Up another £1 today. Up £4 in two days..
Was probably someone trying to give AZ a shake and give someone another chance to get aboard the gravy train! Haha.
Sounds interesting after listening to him on CNBC this week talking about alternatives to Chemotherapy!
Looking back as we're near yrs end. Up 260%+ to date from risky punt when not looking too good back with a yield over 6%, no success in R&D. What a dsmn turnaround since then! It's been, and that's what we do GO LONG on investments.
Gla
Shorters closing :-)
Up over £3 today to £104, as I hoped. Now heading back to £115 IMHO.
Very good news with cancer treatment. A strong buy at this evening’s closing price, IMHO.
All good news
Must be being shorted :-)
DaiIchi has signed a development deal worth initially $4bn and up to $22bn for 3 compounds…..must have outbid AZN for these.
Baffled. Falling on good news!
Why so much ?? anyone got a theory or know anything
No doubt NVG will pop up and tell us all this is grossly overvalued and that he will get in when it drops back into the 800’s. LOL
Yes.
This sounds to be particularly good news..
Consistent strategy.
Seems to be back on the march ( st leger day )
Https://www.lse.co.uk/news/AZN/update-astrazeneca-has-good-results-from-three-cancer-drugs-in-trials-1mtuvvrrouuggwu.html versus Soirot news. MM shenanigans
Many thanks for this info.
Probably the news yesterday the CEO maybe leaving the company?
https://www.thisismoney.co.uk/money/markets/article-12498983/AstraZeneca-boss-Sir-Pascal-Soriot-looks-step-down.html
Does anyone know why did the share price fall today?
The clinical trials results seemed to be fine.
It seems to me that Governments around the world are wrestling with increasingly expensive medications that the people and doctors want to access via public healthcare.
China has its national drug reimbursement list with large discounts to give access to the heatlthcare hospital pharmacies and state funding.
The UK imposes a levy on manufacturers to compensate for increasing costs of drugs
The US seems to be behind the curve….in paying what the manufacturer demands rather than negotiating a lower price to be on the government list….
It does seem to me that pharma may become slightly less profitable….but that may depend on what will the industry be able to claw back through higher charges to non government revenue streams? Or what other concessions it may be able to wring out of the politicians.